While riding high on the popularity of its weight loss drug Zepbound, the company is quietly building a presence in a cutting ...

Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...

On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...

Seamless Therapeutics inks research collaboration with Lilly to develop programmable recombinase-based therapeutics for hearing loss: Dresden, Germany Friday, January 30, 2026, 15 ...